Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_3
2
22%
Ph early_phase_1
1
11%
Ph not_applicable
1
11%
Ph phase_2
1
11%
Ph phase_1
4
44%

Phase Distribution

5

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(3)
Terminated(4)
Other(2)

Detailed Status

Terminated3
Completed3
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 14 (44.4%)
Phase 21 (11.1%)
Phase 32 (22.2%)
N/A1 (11.1%)

Trials by Status

terminated333%
completed333%
unknown222%
withdrawn111%

Recent Activity

0 active trials
Showing 5 of 9
completednot_applicable

PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer

NCT02088775
withdrawnearly_phase_1

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

NCT05111314
terminatedphase_1

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT01285102
completedphase_3

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727
terminatedphase_1

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

NCT02110953
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02088775Not Applicable

PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer

Completed
NCT05111314Early Phase 1

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Withdrawn
NCT01285102Phase 1

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

Terminated
NCT00324727Phase 3

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Completed
NCT02110953Phase 1

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

Terminated
NCT00524316Phase 2

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Terminated
NCT00553683Phase 1

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Unknown
NCT00079027Phase 3

Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

Unknown
NCT01042041Phase 1

Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
9